A. Vekaria

Baseline IL‐22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab

M. Lebwohl, A. Neumann, H. Wen, 2019, The Journal of allergy and clinical immunology.

A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata

M. Lebwohl, G. Singer, E. Guttman‐Yassky, 2018, Archives of Dermatological Research.

Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata

E. Guttman‐Yassky, Lauren Bonomo, Y. Amir, 2017, JAAD case reports.

Phase 2 Randomized, Double-blind Study of IL-17-Targeting with Secukinumab in Atopic Dermatitis.

G. Singer, B. Ungar, E. Guttman‐Yassky, 2020, The Journal of allergy and clinical immunology.

Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity

M. Lebwohl, P. Brunner, E. Guttman‐Yassky, 2017, F1000Research.

Atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity.

M. Lebwohl, P. Brunner, E. Guttman‐Yassky, 2017, F1000Research.